TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
AstraZeneca AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
223,453,000
|
181,475,000
|
165,242,000 |
| Financial expenses |
1,542,000
|
543,000
|
1,523,000 |
| Earnings before taxes |
63,989,000
|
82,755,000
|
-20,662,000 |
| EBITDA |
44,911,000
|
41,721,000
|
29,551,000 |
| Total assets |
446,798,000
|
365,256,000
|
270,063,000 |
| Current assets |
64,566,000
|
37,216,000
|
33,759,000 |
| Current liabilities |
39,899,000
|
24,273,000
|
24,951,000 |
| Equity capital |
357,799,420
|
310,550,700
|
211,508,200 |
| - share capital |
2,054,000
|
2,054,000
|
2,054,000 |
| Employees (average) |
7,543
|
7,248
|
6,875 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
80.1%
|
85.0%
|
78.3% |
| Turnover per employee |
29,624
|
25,038
|
24,035 |
| Profit as a percentage of turnover |
28.6%
|
45.6%
|
-12.5% |
| Return on assets (ROA) |
14.7%
|
22.8%
|
-7.1% |
| Current ratio |
161.8%
|
153.3%
|
135.3% |
| Return on equity (ROE) |
17.9%
|
26.6%
|
-9.8% |
| Change turnover |
41,978,000
|
16,233,000
|
51,179,000 |
| Change turnover % |
23%
|
10%
|
45% |
| Chg. No. of employees |
295
|
373
|
61 |
| Chg. No. of employees % |
4%
|
5%
|
1% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.